Stock Events

Stock Events

Prostatype Genomics AB 

SEK0.107500
2
+SEK0.00+0.47%Friday 11:43

Statistics

Day High
0.1075
Day Low
0.1
52W High
2.28
52W Low
0.0788
Volume
1,388,204
Avg. Volume
8,429,090
Mkt Cap
6.36M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

May 31Expected
Q1 2021
Q1 2024
-0.26
0.07
0.41
0.74
Expected EPS
N/A
Actual EPS
N/A

Financials

-7,492.09%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
594,000Revenue
-44.5MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Myriad Genetics
MYGN
Mkt Cap434.25M
Myriad Genetics provides molecular diagnostic products that include prognostic medicine for prostate cancer, directly competing with Prostatype Genomics' offerings.
Illumina
ILMN
Mkt Cap41.23B
Illumina manufactures sequencing systems that are used in cancer genomics, impacting the broader market including prostate cancer diagnostics.
Fulgent Genetics
FLGT
Mkt Cap591.03M
Fulgent Genetics offers comprehensive genetic testing, including for cancer, which places them in direct competition with Prostatype Genomics in the genomic profiling market.
Pacific Biosciences of California
PACB
Mkt Cap789.51M
Pacific Biosciences offers sequencing technologies that are used in genomic research, including cancer, indirectly competing with Prostatype Genomics.
Qiagen NV
QGEN
Mkt Cap9.24B
Qiagen provides sample to insight solutions including for cancer, with technologies that compete in the genomic diagnostics market.
Quest Diagnostics
DGX
Mkt Cap25.75B
Quest Diagnostics offers diagnostic testing, including for cancers such as prostate cancer, competing with Prostatype Genomics in the diagnostics market.

About

Prostatype Genomics AB (publ) manufactures, markets, and sells prognostic gene tests. The company offers a Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, gleason score, RTqPCR kit, patient database and algorithms, Prostatype Web System (PWS), and tumor stage, as well as calculates the P-score. Its test is based on a database containing prostate cancer patients; and provides decision support for patients and doctors when making a treatment decision. The company was incorporated in 2007 and is headquartered in Nacka Strand, Sweden.
Show More
CEO
Mr. Fredrik Rickman
Employees
7
Country
Sweden
ISIN
SE0023261532
WKN
000A40P4W

Listings

OTC Link
US
PGABF
ST
SE
PROGEN-BT-UN.ST
F
DE
PGO0.F
ST
SE
PROGEN.ST

0 Comments

Share your thoughts

FAQs

What is Prostatype Genomics AB stock price today?▼
The current price of PROGEN.ST is SEK0.11 SEK — it has increased by +0.47% in the past 24 hours. Watch Prostatype Genomics AB stock price performance more closely on the chart.
What is Prostatype Genomics AB stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Stockholm Exchange exchange Prostatype Genomics AB stocks are traded under the ticker PROGEN.ST.
Is Prostatype Genomics AB stock price growing?▼
PROGEN.ST stock has risen by +5.39% compared to the previous week, the month change is a +15.34% rise, over the last year Prostatype Genomics AB has showed a -83.76% decrease.
What is Prostatype Genomics AB market cap?▼
Today Prostatype Genomics AB has the market capitalization of 6.36M
What is Prostatype Genomics AB revenue for the last year?▼
Prostatype Genomics AB revenue for the last year amounts to 594,000 SEK.
What is Prostatype Genomics AB net income for the last year?▼
PROGEN.ST net income for the last year is -44.5M SEK.
How many employees does Prostatype Genomics AB have?▼
As of November 1, 2026, the company has 7 employees.
In which sector is Prostatype Genomics AB located?▼
Prostatype Genomics AB operates in the Health & Wellness sector.
When did Prostatype Genomics AB complete a stock split?▼
The last stock split for Prostatype Genomics AB was on October 31, 2024 with a ratio of 1:1000.
Where is Prostatype Genomics AB headquartered?▼
Prostatype Genomics AB is headquartered in Nacka Strand, Sweden.